Galletti R, Beauverger P, Wild T F
INSERM 404, Immunity and Vaccination, Pasteur Institute of Lyon, France.
Vaccine. 1995 Feb;13(2):197-201. doi: 10.1016/0264-410x(95)93136-w.
We have used vaccinia-measles recombinant viruses to study vaccination in the presence of pre-existing antibody. When mice were vaccinated with recombinants expressing either the haemagglutinin (H) or fusion (F) measles virus (MV) proteins, the humoral response to the MV protein was suppressed by passively administered polyclonal antibody. However, individual monoclonal antibodies (H or F) did not affect the response. Mice whose anti-MV antibody response to H or F was initially suppressed by passive administration of anti-MV antibody were revaccinated 120 days later and gave a normal humoral response to the MV proteins. The VV-H recombinant induces a strong class I CTL response in Balb/c mice. This was not affected by the presence of levels of anti-MV antibody which inhibited the humoral response.
我们已使用痘苗-麻疹重组病毒来研究在已有抗体存在的情况下的疫苗接种情况。当用表达血凝素(H)或融合(F)麻疹病毒(MV)蛋白的重组体对小鼠进行疫苗接种时,被动给予的多克隆抗体可抑制对MV蛋白的体液免疫反应。然而,单个单克隆抗体(H或F)并不影响该反应。其对H或F的抗MV抗体反应最初因被动给予抗MV抗体而受到抑制的小鼠,在120天后再次接种疫苗,并对MV蛋白产生了正常的体液免疫反应。VV-H重组体在Balb/c小鼠中诱导出强烈的I类细胞毒性T淋巴细胞(CTL)反应。这不受抑制体液免疫反应的抗MV抗体水平的影响。